Dana-Farber Cancer Institute to create Chen-Huang Center for EGFR Mutant Lung Cancers
Figure 5: APLN overexpression correlates with worsened prognosis in ovarian cancer patients treated with bevacizumab. (A) APLN expression in patients in APLN-low and APLN-high groups. (B) Kaplan-Meier analysis of disease-free survival (DFS) in patients in APLN-low and APLN-high groups (Median DFS of 14.1 vs. 41.2 months; P = 0.05). (C) APLNR expression in patients in APLNR-low and APLNR-high groups (P < 0.001). (D) Kaplan-Meier analysis of DFS in patients in APLNR-low and APLNR-high groups (P = 0.22). Statistical analysis was performed using Two-tailed unpaired t-test for gene expression levels in A., C and Log-rank test was used for statistical analysis of survival outcome in B., D.
Increased tumor angiogenesis in ovarian cancer is also critical to ovarian cancer metastasis and ascites development.
Several studies have shown that a high level of vascular endothelial growth factor , a key regulator of tumor angiogenesis, is associated with poor prognosis in patients with ovarian cancer.
In the present study, the scientists developed preclinical xenograft models of ovarian cancer that acquire adaptive resistance to anti-VEGF therapeutics.
Using these tumors, they utilized unbiased approaches to identify not only a distinct gene signature associated with resistance development, but also the source of resistance.
The Woo Research Team concluded:
we have used in vivo tumor models that gain adaptive resistance to VEGF-targeting therapeutics to discover a unique molecular signature associated with the anti-VEGF resistance phenotype. These pathways may function as important alternative angiogenic signaling pathways in the presence of VEGF blockade. The present study has thus paved the way for the development of new combination or sequential treatment strategies that may help to counteract the resistance mechanisms. Source:
Impact Journals LLC Journal reference:
Jaiprasart, P. et al . (2020) Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy. Oncotarget . doi.org/10.18632/oncotarget.27307
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology